Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
Officers and directors of cancer treatment developer MacroGenics Inc. have been hit with a shareholder derivative action alleging they breached their fiduciary duties after the company announced three study participant deaths...To view the full article, register now.
Already a subscriber? Click here to view full article